Introduction {#Sec1}
============

Globally, oesophageal cancer is one of the most frequently reported malignancies and a leading cause of cancer deaths^[@CR1]^. In 2008, the disease accounted for around 4 million disability-adjusted life years^[@CR2]^. The cancer is extremely aggressive and prognosis is often poor^[@CR3],[@CR4]^.

Majority of oesophageal cancers (80%) are reported in more deprived nations. Most of these cancers belong to either of the major histologic types: squamous cell carcinoma (SCC) and adenocarcinoma (AC). Although SCCs historically consist of the majority of all cases of this cancer, in recent years we have observed a rapid rise of AC in western countries^[@CR3],[@CR5]^. The risk factors of AC such as increased age, male sex, obesity, gastro-oesophageal reflux disease, cigarette smoking, and diet low in vegetables and fruit have been widely recognized; whereas for SCC, cigarette smoking, alcohol consumption, caustic injury, poor oral hygiene, ingestion of caustic agents, and nutritional deficiencies are major risk factors^[@CR3],[@CR6]^. As many risk factors of oesophageal cancer could be modified, it should be possible to control this disease by preventive measures^[@CR7]^. Therefore, it is important to examine its updated rates of incidence and mortality, particularly with respect to temporal trends.

Prior evaluations studying its global trends are based on figures in late 1990s^[@CR6]--[@CR8]^; have not taken country-specific socioeconomic development when the trends were compared^[@CR6]--[@CR9]^, or compared the incidence/mortality trends in one or few selected years^[@CR10]^. It remains unknown whether the effect of socioeconomic status on the development of SCC vs. AC is different in different countries. In some western countries surveillance of Barrett's esophagus is offered, though a tiny fraction of the total burden of oesophageal cancer arises from Barrett's esophagus.

This study aimed to analyze its global patterns and temporal trends of oesophageal cancer by retrieval of data from national databases. We examined the incidence ratio between AC and SCC and its correlation with socioeconomic development across various countries on a global basis.

Methodology {#Sec2}
===========

Data retrieval {#Sec3}
--------------

Estimates of incidence and mortality rates of oesophageal cancer were collected from the GLOBOCAN database for 2012^[@CR1]^. The disease coding is ICD-10 C15. We used a study approach similar to recent evaluations on prostate, liver, bladder and pancreatic cancer^[@CR11]--[@CR14]^. Figures of the Gross Domestic Product (GPD) and Human Development Index (HDI) for each nation were obtained^[@CR15]^, and incidence/mortality figures from GLOBOCAN of the same year^[@CR1]^. HDI is determined by income per capita, period of education and life expectancy^[@CR15]^. We extracted data from various sources, and restricted to those databases with no less than 15 calendar years of incidence/mortality figures. For incidence data, we retrieved country-specific registries based on the Cancer Incidence in Five Continents (CI5) volumes I-X^[@CR16]^. With an aim to obtain the most updated figures, we used data from the United States^[@CR17]^ and Europe (European Cancer Observatory and NORDCAN) which are publicly available^[@CR18],[@CR19]^. These databases, including GLOBOCAN, have been used extensively in studies examining the incidence trends of various cancers on a global basis (Supplementary Table [1](#MOESM1){ref-type="media"}). Data provided by these databases are comprehensive, and have been recognized as the standards for quality among cancer registries^[@CR1],[@CR17]--[@CR22]^. Supplementary Table [2](#MOESM1){ref-type="media"} shows the methods by which the data were obtained and their quality. Based on the International Classification of Diseases 10^th^ revision (ICD-10 C15), we categorized incidence data into various groups. Data on mortality were categorized using ICD 9^th^ (150·0) up to 1991 and 10^th^ version (C15) thereafter. The incidence of AC and SCC in 2012 was obtained based on the ICD for Oncology-3 presented in CI5^[@CR10],[@CR16],[@CR23]^: ACs: 8140--8141, 8143--8145, 8190--8231, 8260--8263, 8310, 8401, 8480--8490, 8550--8551, 8570--8574, 8576; SCC: 8050--8078 and 8383--8084. To obtain mortality figures, the WHO mortality data series were used. We only included data with quality that reached medium level or above^[@CR24]^, so that complete and accurate data with wide coverage could be analyzed. The database used death certificates to ascertain causes of death. The ASRs were based on the standard population of the world^[@CR25]^. More developed nations were defined as European nations, New Zealand, Australia and Northern America as well as Japan, while other countries and regions were considered as less developed nations^[@CR1]^.

Study Design {#Sec4}
------------

To correlate rates of incidence and mortality vs. the socioeconomic indices (HDI/GDP per capita), a cross-sectional association study was performed. To examine the incidence/mortality trends in various nations based on Average Annual Percent Change (AAPC), we adopted a retrospective review of published age-standardized incidence/mortality rates from international or national data registries by joinpoint regression.

Statistical Analysis {#Sec5}
--------------------

The ASRs of incidence and mortality, as well as the AC: SCC incidence ratios of each country^[@CR10]^ were correlated with the two socioeconomic indicators. We used simple linear regression and examined the goodness-of-fit, which were represented by correlation coefficients. We employed regression analysis via joinpoints to evaluate the trends of incidence/mortality^[@CR26]^. We conducted logarithmic transformation of the incidence/mortality rates and calculated standard errors approximated binomially. We specified a maximum of 3 joinpoints was specified as the analysis option. The intervals of average annual percentage change (AAPC) were evaluated. We calculated the AAPC as an average of APCs by geometric weighting. Weights equal to the length of each segment were assigned for the time interval specified^[@CR27]^. We compared the magnitude of AAPC with zero which could generate the statistical significance of AAPC, and we defined a trend as stable if the AAPC was insignificant. We considered all p values \< 0·05 as reaching statistical significance. This study obtained ethics approval from the Survey and Behavioral Research Ethics Committee of CUHK.

Results {#Sec6}
=======

Incidence, mortality and histologic subtype ratios of esophageal cancer {#Sec7}
-----------------------------------------------------------------------

In 2012, there were 455,784 new diagnoses of oesophageal cancer and 400,169 mortality related to the cancer (Tables [1](#Tab1){ref-type="table"}**/** and [2](#Tab2){ref-type="table"}). Around 81% of incident cases and 82% of all mortality were reported in underdeveloped nations. Rates of incidence and mortality were greater in relatively less resourced regions than less deprived countries by 1·5 to 1·7-fold in men, and by 3·4 to 4-fold in women. On a global basis, the rates of incidence varied by 20-fold. Among male, the highest rates of incidence were reported in Eastern Asia (with ASR = 16·9 per 100,000), Southern Africa (13·7), Eastern Africa (11·9) and Northern Europe (8·1), and the lowest in Western Africa (0·8), Central America (1·7), Northern Africa (2·4) and Western Asia (2·9) (Table [1](#Tab1){ref-type="table"}). In female individuals, the greatest rates were reported in middle Africa (ASR per 10,000 = 7·8), Western Africa (6·7), Eastern Asia (5·4) and Eastern Africa (4·2), while the lowest in Micronesia/Polynesia (0·2), Southern Europe (0·6), Central America (0·6) and South-Eastern Asia (1·0). The results were shown in Table [2](#Tab2){ref-type="table"}.Table 1Age standardized incidence/mortality of cancer of oesophagus in various regions (male).World regionsPopulation Male (1,000)IncidenceMortalityIncidence to mortality rationASRnASR**Africa**549,44516,0625.614,7025.31.09Eastern Africa180,2439,80511.912,9826.40.76Middle Africa69,1791,2024.28,94411.20.13Northern Africa106,1471,8642.41,1094.01.68Southern Africa29,7352,52313.71,7202.31.47Western Africa164,1416680.82,32012.80.29**Asia**2,179,003240,14211.4207,9849.91.15Eastern Asia813,296183,02416.9155,26214.11.18South-Eastern Asia305,2259,3663.68,5453.31.10South-Central Asia933,78645,3156.541,9226.01.08Western Asia126,6972,4372.92,2552.71.08**America\***303,51430,3505.526,9964.81.12Caribbean20,9511,0564.69544.11.10Central America82,2271,1411.71,0541.61.08South America200,33613,2867.010,7735.61.23North America173,20914,8675.414,2155.01.05**Europe**355,27535,1005.830,3354.91.16Central and Eastern Europe138,24911,0445.69,8925.01.12Northern Europe49,5747,6188.16,9517.21.10Southern Europe74,9004,5163.24,0912.81.10Western Europe92,55311,9226.89,4015.01.27**Oceania**18,8591,3545.21,2004.51.13Australia/New Zealand13,6321,2515.41,1064.71.13Melanesia4,628863.6773.41.12Micronesia/Polynesia258173.1173.21.00More developed regions604,00867,7486.456,0995.21.21Less developed regions2,975,297255,26010.1225,1189.01.13**World**3,579,305323,0089.0281,2177.71.15ASR = Age standardized rate per 100,000 in 2012. Source: GLOBOCAN 2012. Numbers are rounded to the nearest 10 or 100, and may not add up to the total. \*America = WHO Americas region (PAHO).Table 2Age standardized incidence/mortality of cancer of oesophagus in various regions (female).World regionsPopulation Female (1,000)IncidenceMortalityIncidence to mortality rationASRnASR**Africa**549,60811,4593.510,5423.31.09Eastern Africa182,46910,2114.29,3913.91.09Middle Africa69,6447,4687.86,8607.31.09Northern Africa105,3536812.06301.81.08Southern Africa30,8161,2481.51,1511.41.08Western Africa161,3271,7196.71,5826.21.09**Asia**2,081,150100,3334.390,7353.81.11Eastern Asia777,37466,8995.459,8604.51.12South-Eastern Asia306,0082,9421.02,6590.91.11South-Central Asia881,51428,4983.926,3703.61.08Western Asia116,2531,9942.11,8461.91.08**America\***310,3609,6401.48,0071.11.20Caribbean21,3133431.22911.01.18Central America83,6324620.64290.51.08South America205,4154,8922.03,6601.51.34North America176,5853,9431.13,6271.01.09**Europe**381,74710,7931.29,2010.91.17Central and Eastern Europe155,7012,6080.87,4271.10.35Northern Europe51,2523,4742.72,1360.61.63Southern Europe78,3931,1190.63,1212.30.36Western Europe96,4003,5921.61,0060.53.57**Oceania**18,7465511.74671.41.18Australia/New Zealand13,7155071.74241.31.20Melanesia4,451431.4421.41.02Micronesia/Polynesia58010.210.21.00More developed regions637,29418,3961.215,2490.91.21Less developed regions2,880,901114,3804.1103,7033.61.10**World**3,518,195132,7763.1118,9522.71.12ASR = Age standardized rate per 100,000 in 2012. Source: GLOBOCAN 2012. Numbers are rounded to the nearest 10 or 100, and may not add up to the total. \*America = WHO Americas region (PAHO).

In 2012, the variation of rates of mortality was approximately 10-fold on a global basis. In male, the highest rate of mortality were estimated in the Eastern Asia (14·1), Western Africa (12·8) and middle Africa (11·2); while in female, the highest death rate was observed in these three regions (ASR of mortality = 4·5, 6·2 and 7·3 per 100,000, respectively). The lowest rates of mortality were reported in Central America (1·6), Southern Africa (2·3), and Western Asia (2·7) in men. For women, Central America (0·5) and South-Eastern Asia (0·9) reported the lowest rates of mortality. Regions with the largest incidence: mortality ratio in men included Southern Africa (1·47), Western Europe (1·27), and South America (1·23). In women, the highest ratios were reported for female in Western Europe (3·57), Northern Europe (1·63) and South America (1·34).

Table [3](#Tab3){ref-type="table"} shows the ratio between the incidence of AC and SCC in all countries where data were available^[@CR10]^. The AC:SCC ratios were in general higher in male individuals. Countries in Eastern and South-East Asia, as well as sub-Saharan Africa had low AC:SCC ratios. When compared with SCC, many countries in the Northern America (e.g. Canada, the US), Northern Europe and Western Europe such as the Netherlands, UK, and Ireland had larger incidence of AC in men.Table 3The ratio between incidence of adenocarcinoma and squamous cell carcinoma in all countries.MaleFemaleAC:SCC ratio (male)AC:SCC ratio (female)ACSCCACSCCASRNASRNASRNASRN***Sub-Saharan Africa***Angola0.3125.92380.273.31550.0500.045Benin0.111.3310.000.370.0320.000Botswana0.8514.4860.224.0300.0580.067Burkina Faso0.132.0510.021.2580.0590.034Burundi1.01717.83430.497.81980.0500.045Cameroon0.131.4770.010.6400.0390.025Cape Verde0.000.310.000.000.0000.000Central African Republic0.222.7320.111.7260.0630.038Chad0.132.0540.121.4440.0560.045Comoros0.7111.8210.316.6130.0480.077Congo, Democratic Republic of0.3375.16970.1172.23700.0530.046Congo, Republic of0.111.4140.000.230.0710.000Cote d Ivoire0.161.5930.010.4250.0650.040Djibouti0.203.690.203.8110.0000.000Equatorial Guinea0.102.170.000.310.0000.000Eritrea0.223.8390.234.5660.0510.045Ethiopia0.1211.94660.2464.410770.0450.043France, La Reunion0.427.8360.000.430.0560.000Gabon0.112.9150.101.590.0670.000Ghana0.030.8680.010.2170.0440.059Guinea0.110.8190.000.140.0530.000Guinea-Bissau0.000.830.000.000.0000.000Kenya1.19219.317670.76714.314810.0520.045Lesotho1.1619.81010.5410.6810.0590.049Liberia0.111.190.000.230.1110.000Madagascar0.63010.65930.2124.32670.0510.045Malawi1.45126.510150.93819.88510.0500.045Mali0.121.4510.010.4200.0390.050Mauritania0.101.1100.000.110.0000.000Mauritius0.324.2280.112.1190.0710.053Mozambique0.63511.86850.3236.74930.0510.047Namibia0.112.2130.000.540.0770.000Niger0.121.1480.000.270.0420.000Nigeria0.070.31370.070.31330.0510.053Rwanda0.5118.82080.254.21190.0530.042Senegal0.121.1320.000.3120.0630.000Sierra Leone0.111.2120.000.330.0830.000Somalia0.61210.62380.4109.32330.0500.043South African Republic1.016312.921210.71626.214250.0770.114South Sudan0.61611.02980.3107.02100.0540.048Swaziland0.519.1250.102.9100.0400.000Tanzania0.77012.212880.3365.87630.0540.047The Gambia0.101.050.000.000.0000.000Togo0.243.8610.121.9370.0660.054Uganda1.37923.315180.5369.87260.0520.050Zambia0.61710.43110.3117.12400.0550.046Zimbabwe2.6909.03060.9407.12890.2940.138***Northern Africa & Western Asia***Algeria0.3380.6840.060.3390.4520.154Armenia0.7121.5260.130.5180.4620.167Azerbaijan1.9784.21710.5262.81600.4560.163Bahrain1.540.730.311.021.3330.500Egypt0.51642.37360.31021.24390.2230.232Gaza Strip and West Bank0.3100.7220.020.3130.4550.154Georgia0.4301.0670.1120.8780.4480.154Iraq0.9470.7370.2140.6401.2700.350Israel0.470.8150.120.590.4670.222Jordan0.220.550.110.830.4000.333Kuwait0.360.6130.120.5130.4620.154Lebanon0.5101.1230.010.270.4350.143Libya0.5661.11450.1170.71040.4550.163Morocco0.641.290.211.060.4440.167Oman0.631.260.412.530.5000.333Qatar0.4391.0820.2111.3930.4760.118Saudi Arabia0.771.6150.110.770.4670.143Sudan1.81694.03730.6664.14340.4530.152Syrian Arab Republic0.4260.9580.170.7450.4480.156Tunisia0.290.4200.140.4240.4500.167Turkey1.13523.110220.2822.810590.3440.077United Arab Emirates0.571.2160.422.2140.4380.143Western Sahara0.100.310.000.000.0000.000Yemen1.4633.01370.6343.82230.4600.152***Central Asia***Afghanistan1.38410.57120.5337.04900.1180.067Bangladesh1.790114.176190.63398.949870.1180.068Bhutan0.725.8170.314.5120.1180.083India0.421744.9248550.16802.6138840.0870.049Iran, Islamic Republic of0.92728.226260.92537.221920.1040.115Kazakhstan1.710314.08560.5516.26660.1200.077Kyrgyzstan0.7116.1960.253.2730.1150.068Maldives0.615.360.202.430.1670.000Nepal0.4353.22920.1121.51640.1200.073Pakistan0.42573.521800.31694.125410.1180.067Sri Lanka0.6715.05920.4505.16880.1200.073Tajikistan2.13617.53040.71510.02120.1180.071Turkmenistan2.64021.33411.12215.23120.1170.071Uzbekistan0.8676.45570.3364.75150.1200.070***Eastern/South-East Asia***Brunei0.000.410.101.110.0000.000Cambodia0.273.91520.131.2720.0460.042China0.8700917.51511460.324896.3596390.0460.042Indonesia0.1671.414270.0330.66370.0470.052Japan0.463310.5156400.11641.628970.0400.057Korea, Democratic Republic of0.4549.011570.1211.83660.0470.057Korea, Republic of0.2785.719250.0210.41660.0410.127Lao PDR0.010.9160.000.380.0630.000Malaysia1.01211.51770.5621.01230.6840.504Mongolia1.0819.91560.8813.91400.0510.057Myanmar0.59910.823120.2423.99430.0430.045Philippines0.61541.23450.1500.41430.4460.350Singapore0.3122.5920.130.5260.1300.115Thailand0.31144.117430.1390.83910.0650.100Timor-Leste0.102.480.100.820.0000.000***Central and Southern America & Caribbean***Argentina2.04734.210200.41631.76030.4640.270Bahamas0.612.140.100.410.2500.000Barbados0.822.550.210.520.4000.500Belize0.913.230.301.220.3330.000Bolivia0.3101.0330.130.3110.3030.273Brazil2.018738.178040.67062.124690.2400.286Chile0.7784.14410.3391.52300.1770.170Colombia1.12161.93570.2530.92200.6050.241Costa Rica0.8181.2280.240.4130.6430.308Cuba1.71476.05100.4391.31320.2880.295Dominican Republic0.4191.3630.3120.9400.3020.300Ecuador0.3231.1780.2160.3240.2950.667El Salvador0.5151.6440.160.5210.3410.286France, Guadeloupe1.344.5150.210.720.2670.500France, Martinique1.033.5110.110.420.2730.500French Guyana1.414.850.000.000.2000.000Guatemala0.5221.6720.3130.9450.3060.289Guyana0.611.950.100.420.2000.000Haiti0.5171.8620.3121.0390.2740.308Honduras0.5111.5360.140.4130.3060.308Jamaica0.9132.9400.230.6100.3250.300Mexico0.41901.26230.1740.42470.3050.300Nicaragua0.471.4230.000.120.3040.000Panama0.6101.8310.230.5110.3230.273Paraguay1.0263.5890.381.0270.2920.296Peru0.5571.41800.1220.5740.3170.297Puerto Rico0.9252.4640.3100.5230.3910.435Suriname0.310.920.100.520.5000.000Trinidad and Tobago0.531.7110.000.000.2730.000Uruguay2.1516.61570.6262.1780.3250.333Venezuela0.5571.51920.1190.4650.2970.292***Northern America***Canada3.08981.54620.41580.72691.9440.587United States of America3.687851.843340.413090.720902.0270.626***Eastern Europe***Belarus0.8505.93560.1120.3290.1400.414Bulgaria0.9552.11250.1130.3260.4400.500Czech Republic2.21883.42850.3360.7730.6600.493Hungary1.3945.64070.2250.7700.2310.357Poland0.51483.49890.1430.73110.1500.138Republic of Moldova0.7152.7620.120.140.2420.500Romania0.81213.55270.1310.4800.2300.388Russian Federation0.86995.649530.12320.712680.1410.183Slovakia0.8295.62090.280.7340.1390.235Ukraine0.92714.513390.2910.31650.2020.552***Northern and Western Europe***Austria2.015032160.2240.5500.6940.480Belgium3.53513.93590.6801.41590.9780.503Denmark3.11692.41220.8501.5911.3850.549Estonia0.444380.110.5100.1050.100Finland1.8941.8960.3250.8600.9790.417France (metropolitan)1.68864.423310.32641.48730.3800.302Germany2.217894.736590.33341.110500.4890.318Iceland3.9102.770.620.831.4290.667Ireland5.41832.9951442.2941.9260.468Latvia0.9156.2970.260.9240.1550.250Lithuania1.1256.31390.270.6240.1800.292Luxembourg3.4132.9110.631.161.1820.500Norway2.31021.5650.4250.7351.5690.714Sweden2.11981.51410.4440.7781.4040.564Switzerland2.61973.32370.5461.41110.8310.414The Netherlands7.111022.84331.22371.52762.5450.859United Kingdom7.243512.515101.41120216172.8810.693***Southern Europe***Albania0.491.3260.130.5120.3460.250Bosnia Herzegovina0.4131.3380.150.5160.3420.313Croatia0.9324.51680.190.5330.1900.273Cyprus0.860.650.220.331.2000.667Macedonia0.340.9140.110.230.2860.333Greece0.4441.21290.1100.2310.3410.323Italy0.64041.59190.1930.43700.4400.251Malta2.391.350.110.651.8000.200Montenegro0.632.2100.210.730.3000.333Portugal1.31214.74050.1170.4570.2990.298Serbia0.6443.42520.1120.7680.1750.176Slovenia0.7123540.130.5140.2220.214Spain1.35273.112090.2930.52340.4360.397***Oceania***Australia3.46571.93650.51191.12851.8000.418Fiji0.422.6100.00000.2000.000French Polynesia0.714.870.00000.1430.000Guam0.402.530.00000.0000.000New Caledonia0.714.770.00000.1430.000New Zealand4.01501.5570.6271.2602.6320.450Papua New Guinea0.583.5560.371.6360.1430.194Samoa0.00000.20110.0000.000Solomon Islands0.000.310.00000.0000.000Vanuatu0.00000.00000.0000.000AC: adenocarcinoma; ASR: age-standardized rate; SCC: squamous cell carcinoma.

Correlation: rates of incidence/mortality vs. HDI and GDP per capita {#Sec8}
--------------------------------------------------------------------

The incidence of AC increased with HDI in men (r^2^ = 0·224, r = 0·473) and women (r^2^ = 0·037, r = 0·192), and similarly for its relationship with GDP (r^2^ = 0·288, r = 0·537 and r^2^ = 0·0716, r = 0·268 for male and female, respectively). For SCC, its incidence was inversely correlated with HDI (r^2^ = 0·051, r = −0·226, p = 0·004 for men; r^2^ = 0·098, r = −0·313, p \< 0·001 for women) and GDP per capita (r^2^ = 0·040, r = −0·200, p = 0·012 for men; r^2^ = 0·0437, r = −0·209, p = 0·009 for women) (Fig. [1A to D](#Fig1){ref-type="fig"}). HDI was correlated with the ratio between the standardized incidence of AC and SCC (r² = 0·287, r = 0·535 \[men\]; r² = 0·437, r = 0·661 \[women\]) and GDP per capita (r² = 0·353, r = 0·594 \[men\]; r² = 0·302, r = 0·550 \[women\], all p \< 0·001). Similar trend was observed when the ratio between the absolute incidence of AC and SCC was used (Fig. [2A to D](#Fig2){ref-type="fig"}).Figure 1(**A**) Relationship between incidence of oesophageal adenocarcinoma and Human Development Index in male (upper panel) and female (lower panel). (**B**) Relationship between age-standardised incidence of oesophageal squamous cell carcinoma and Human Development Index in male (upper panel) and female (lower panel). (**C**) Relationship between age-standardised incidence of oesophageal adenocarcinoma and Gross Domestic Product per capita in male (upper panel) and female (lower panel). (**D**) Relationship between age-standardised incidence of oesophageal squamous cell carcinoma and Gross Domestic Product per capita in male (upper panel) and female (lower panel).Figure 2(**A**) Relationship between the ratio of age-standardised incidence rates of adenocarcinoma (AC): squamous cell carcinoma (SCC) and Human Development Index in male (upper panel) and female (lower panel). (**B**) Relationship between the ratio of age-standardised incidence rates of adenocarcinoma (AC): squamous cell carcinoma (SCC) and Gross Domestic Product per capita in male (upper panel) and female (lower panel). (**C**) Relationship between the ratio of crude incidence rates of adenocarcinoma (AC): squamous cell carcinoma (SCC) and Human Development Index in male (upper panel) and female (lower panel) (**D**) Relationship between the ratio of crude incidence rates of adenocarcinoma (AC): squamous cell carcinoma (SCC) and Gross Domestic Product per capita in male (upper panel) and female (lower panel).

Time trends {#Sec9}
-----------

The global trends of incidence and mortality according to gender were shown in Supplementary Figure [1](#MOESM1){ref-type="media"}. Among male subjects, 3 countries reported increasing incidence, 7 countries reported decreasing incidence, and 31 countries had stable rates of incidence. Among women, one country showed increasing incidence and 4 showed declining incidence. Turning to mortality rates, 2 countries had increasing trends, 10 countries reported decreasing male mortality and 29 nations reported relatively stable time trends in male subjects. Five countries had decreasing death rates and 36 countries had stable death rates in female populations.

### Latin America/the Caribbean {#Sec10}

All countries in this continent had stable incidence trends in the past decade of analysis (Fig. [3A](#Fig3){ref-type="fig"}). The ASR mortality rate reported a decline in Brazilian men (AAPC −1.2, 95% C.I. −1.5, −0.8) and women (AAPC −1.6, 95% C.I. −2.3, −0.9). Columbia also had a significant reduction in mortality among men (AAPC −4.6, 95% C.I. −5.8, −3.4) and women (AAPC −6.1, 95% C.I. −7.5, −4.6) (Fig. [3B](#Fig3){ref-type="fig"}).Figure 3(**A**) Incidence trend of oesophageal cancer in male (left panel) and female (right panel). (**B**) Mortality trend of oesophageal cancer in male (left panel) and female (right panel).

### Northern America {#Sec11}

A reduction in incidence was reported in male (AAPC −5·3, 95% C.I. −6·6, −3·9) and female (AAPC −4·6, 95% C.I. −8·5, −0·4) Black American individuals. A modest reduction in death rates was observed among male populations (AAPC −1·2, 95% C.I. −1·6, −0·8) and women (AAPC −1·7, 95% C.I. −2·4, 0·9) in the United States irrespective of ethnicity.

### Asia {#Sec12}

China (AAPC −5·3, 95% C.I. −6·5, −4), Singapore (AAPC −5·8, 95% C.I. −9·5, −1·9) and Israel (AAPC −3·2, 95% C.I. −5·1, −1·3) reported an incidence reduction in male, and the former two also experienced a decrease in female (China: AAPC −5·6, 95% C.I. −7·6, −3·4; Singapore: AAPC −12·3, 95% C.I. −17·3, −6·9). There was a substantial decline in mortality in Japanese men (AAPC −2·3, 95% C.I. −3. 2, −1·5)  and women (AAPC −0.8, 95% C.I. −1.6, 0).

### Oceania {#Sec13}

The incidence decreased in Australia in female subjects (AAPC −2·5, 95% C.I. −3·8, −1·2). All other trends were stable.

### Northern Europe {#Sec14}

Only the United Kingdom (AAPC 1·4, 95% C.I.0·9, 1·9) and Denmark (AAPC 2.9, 95% C.I. 1.1, 4.7) reported an incidence increase among male. The United Kingdom also showed a mortality reduction among both male (AAPC −0·6, 95% C.I. −0·9, −0·3) and female (AAPC −1·6, 95% C.I. −2·2, −1·1). The majority of the countries had stable incidence and mortality rates.

### Western Europe {#Sec15}

The incidence rate was found to increase in the Netherlands in male populations (AAPC 3, 95% C.I. 2, 4) and female (AAPC 2·3, 95% C.I. 1·3, 3·2) individuals. France reported a decline in incidence (AAPC −3·7, 95% C.I. −5, −2·5) and mortality rates (AAPC −3·4, 95% C.I. −3·9, −2·9) among men.

### Southern Europe {#Sec16}

Italy and Croatia were two countries that had declines in incidence and mortality rates in male populations. Slovenia showed a decline in mortality among women (AAPC −4·6, 95% C.I. −7·9, −1·3).

### Eastern Europe {#Sec17}

Poland (AAPC −7·1, −12, 1·9) reported a substantial reduction in incidence in men.  Among men, Bulgaria (AAPC 2.8, 95% C.I. 0.5, 5.1) had a rise in mortality while Poland (AAPC −2.4, 95% C.I. −3.5, −1.3) and Slovakia (AAPC −2.1, 95% C.I. −3.8, −0.4) reported a decline in mortality.

Discussion {#Sec18}
==========

This study evaluated the worldwide incidence/mortality rates of oesophageal cancer based on existing data. It was found that the incidence and mortality showed wide variations on a global basis. In men, Eastern Asia, Southern Africa and Eastern Africa had the highest number of new diagnoses - mostly SCC. The greatest mortality in male was found in Middle Africa, Western Africa and Eastern Asia. The highest incidence: mortality ratio was reported in Northern and Southern Africa among male, while in Western Europe and Southern America among female.

We found that HDI and GDP per capita were both correlated with AC:SCC ratios in incidence. The correlation coefficients for HDI and GPD *per capita* for the incidence of oesophageal cancer are large. One of the important findings includes the incidence decline in Black America, Singapore and China in men and women. In men, mortality rates increased drastically in less developed nations including the Philippines and Bulgaria. In women, a substantial decrease in mortality was reported for Columbia and Slovenia.

Findings from the present study corroborate those of previous literature. Populations in Asia such as Northern Iran^[@CR28]^, Central Asia and China^[@CR29]^, as well as Eastern Africa^[@CR30]--[@CR32]^, have high incidence rates - so that these regions were collectively named as the "oesophageal cancer belt"^[@CR10]^. The higher incidence rates in these regions may reflect the changing epidemiology of the two histologic types of esophageal cancer (SCC vs. AC) in recent years, such as in Iran where the rates of AC were among the highest in the Central Asian region, particularly in women^[@CR33]^. Some nations reported greater rates of AC when compared with that of SCC, including Northern/Western Europe and Northern America.

This study showed that nations with higher socioeconomic developement had higher AC:SCC ratio in correlation analyses. Poor oral hygiene and poverty have been associated with a higher SCC risk. In addition, there has been rising prevalence of obesity (a risk factor for AC)^[@CR10]^ but declining tobacco smoking (risk of SCC) in more developed nations, which may underpin these correlation trends. Probable explanations for the reduction of mortality trends may consist of technological advancement of oesophageal cancer, such as improvements in endoscopic detection and therapy for early stage disease. These consist of minimally invasive esophagectomy^[@CR3]^--which when accompanied by a strategy with conjoint use of laparoscopic and thoracoscopic techniques, can lead to a very low rate of postoperative mortality (1.7% within 30 days) and a reduction in pulmonary complications, when compared with open surgery. With the advances in endoscopic surveillance programs after Barrett's esophagus is diagnosed, physicians could detect more early stage cancer and this could facilitate earlier management^[@CR3]^. However, some countries including Bulgaria and the Philippines showed escalating rates of cancer death in women. This observation could be explained by the capacities and accessibility of healthcare services which are crucial for early diagnosis and management. The exact reasons on the rise of mortality rates in these countries are yet to be explored. It should be noted that the AC:SCC ratio only exceeded 1 in men in most developed nations. SCC was still a predominate type of oesophageal cancer as reported in this study. Arnold and colleagues^[@CR10]^ previously analyzed the total numbers of AC and SCC in 2012, and reported that SCC was a disproportionally common histologic type when compared to AC on a global basis.

This study updated the incidence and mortality of oesophageal cancer, and explored its time trends and global variability by high quality data from recognized databases. Nonetheless, this study has some limitations. Firstly, cancer diagnoses could be under-reported and may induce bias in cancer registration, particularly in nations where resources are limited^[@CR29]^. On the other hand, in nations where figures were derived from only one cancer registry situated in more developed areas, the estimates might have overestimated the real figures especially in those countries with large areas of underdeveloped regions. Also, less than half of the world's nations provided high quality incidence/mortality data. Therefore, the incidence and mortality figures could have a certain degree of bias, especially in underprivileged nations.

In summary, the incidence of esophageal cancer decreased in the majority of nations, yet the death rates in male populations increased in some countries, especially in the Portugal and Bulgaria. With global expansion in population size, a further increase in its global health burden could be huge -- particularly adenocarcinoma that is positively correlated with socioeconomic development. Therefore, more expenditure will be required to sustain its diagnosis and treatment. In the community, more resources should also be committed to primary prevention strategies.
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